COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,193 Articles (22,713 medRxiv, 8,480 bioRxiv)

Most recent first Previous |  Page 1257: Articles 12561-12570  | Next

Monitoring populations at increased risk for SARS-CoV-2 infection in the community
Pritchard, E., Jones, J., Vihta, K., Stoesser, N., Matthews, P. C., Eyre, D. W., House, T., Bell, J. I., Newton, J. N., Farrar, J., Crook, D., Hopkins, S., Cook, D., Rourke, E., Studley, R., Diamond, I., Peto, T., Pouwels, K. B., Walker, A. S.
10.1101/2021.09.02.21263017 — Posted: 2021-09-05
Expected Rates of Select Adverse Events following Immunization for COVID-19 Vaccine Safety Monitoring
Abara, W. E., Gee, J., Mu, Y., Delorey, M. J., Ye, T., Shay, D. K., Shimabukuro, T.
10.1101/2021.08.31.21262919 — Posted: 2021-09-05
MITIGATING THE 4th WAVE OF THE COVID-19 PANDEMIC IN ONTARIO
Cipriano, L. E., Haddara, W. M. R., Sander, B.
10.1101/2021.09.02.21263000 — Posted: 2021-09-05
No difference in risk of hospitalisation between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway
Veneti, L., Valcarcel Salamanca, B., Seppala, E., Starrfelt, J., Storm, M. L., Bragstad, K., Hungnes, O., Boas, H., Kvale, R., Vold, L., Nygard, K., Buanes, E. A., Whittaker, R.
10.1101/2021.09.02.21263014 — Posted: 2021-09-05 Discussion: Onsite
The comparability of Anti-Spike SARS-CoV-2 antibody tests is time-dependent: a prospective observational study
Perkmann, T., Mucher, P., Perkmann-Nagele, N., Radakovics, A., Repl, M., Koller, T., Schmetterer, K. G., Bigenzahn, J. W., Leitner, F., Jordakieva, G., Wagner, O. F., Binder, C. J., Haslacher, H.
10.1101/2021.08.26.21262426 — Posted: 2021-09-05
Comparative quantitative analysis of SARS-CoV-2 Spike neutralizing antibody titers following two anti COVID-19 vaccines in India
GV, C., Srikantam, A.
10.1101/2021.08.28.21262753 — Posted: 2021-09-05
The association between SARS-CoV-2 infection and neuronal damage: A population-based nested case-control study
Aziz, N. A., Santos, M. L. S., Breteler, M. M. B.
10.1101/2021.09.02.21263019 — Posted: 2021-09-05
How Informative were Early SARS-CoV-2 Treatment and Prevention Trials? A longitudinal cohort analysis of trials registered on clinicaltrials.gov
Hutchinson, N., Klas, K., Carlisle, B. G., Kimmelman, J., Waligora, M.
10.1101/2021.08.25.21262155 — Posted: 2021-09-05
Using multivariate models to examine the impact of COVID-19 pandemic and gender differences on health and health care
Ye, J., Ren, Z.
10.1101/2021.09.02.21263055 — Posted: 2021-09-05
Immunogenicity and Safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CoV) in patients with malignancy
Ariamanesh, M., Porouhan, P., PeyroShabany, B., Fazilat-Panah, D., Dehghani, M., Nabavifard, M., Hatami, F., Fereidouni, M., Welsh, J. S., Javadinia, S. A.
10.1101/2021.09.02.21262760 — Posted: 2021-09-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).